Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4629089 | 0.81 | HTR2A (0.31) | — | |
| SCHEMBL4630162 | 0.74 | TAAR1 (0.61) | TAAR1 | |
| SCHEMBL14370502 | 0.71 | TAAR1 (0.41) | TAAR1 | |
| SCHEMBL4630003 | 0.69 | P2RX7 (0.36) | TAAR1 | |
| SCHEMBL4629861 | 0.69 | LMNA (0.38) | — | |
| SCHEMBL8089494 | 0.67 | CTRC (0.40) | — | |
| SCHEMBL4629682 | 0.66 | SIGMAR1 (0.37) | TAAR1 | |
| SCHEMBL3790392 | 0.66 | GABRA1 (0.46) | TAAR1 | |
| SCHEMBL28605180 | 0.66 | NOTUM (0.34) | — | |
| Ammonia Solution, Strong SCHEMBL233672 | 0.66 | CTRC (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1981497-A2 | USE OF SUBSTITUTED 2-IMIDAZOLE OF IMIDAZOLINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-10-22 | — | — | EP | claimed |
| WO-2007085557-A2 | USE OF SUBSTITUTED 2-IMIDAZOLE OF IMIDAZOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-02 | — | — | WO | claimed |
| EP-1981497-A2 | USE OF SUBSTITUTED 2-IMIDAZOLE OF IMIDAZOLINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-10-22 | — | — | EP | disclosed |
| WO-2007085557-A2 | USE OF SUBSTITUTED 2-IMIDAZOLE OF IMIDAZOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-02 | — | — | WO | disclosed |